Stella Pharma Corporation (4888.T)
JPY 328.0
(0.31%)
JPY 328.0
(0.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -723.85 Million JPY | 2.07% |
| 2022 | -738.34 Million JPY | -1.58% |
| 2021 | -726.85 Million JPY | -16.91% |
| 2020 | -621.69 Million JPY | -6807.77% |
| 2019 | -7.82 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -156.32 Million JPY | 48.92% |
| 2023 Q2 | -138.93 Million JPY | 15.12% |
| 2023 FY | - JPY | 2.07% |
| 2023 Q4 | -293.04 Million JPY | -80.38% |
| 2023 Q3 | -162.45 Million JPY | -16.93% |
| 2023 Q1 | -163.68 Million JPY | 44.5% |
| 2022 Q3 | -127.5 Million JPY | 21.42% |
| 2022 FY | - JPY | -1.58% |
| 2022 Q4 | -294.89 Million JPY | -131.27% |
| 2022 Q2 | -162.27 Million JPY | 0.0% |
| 2021 FY | - JPY | -16.91% |
| 2020 FY | - JPY | -6807.77% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 175.551% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -48.291% |
| GNI Group Ltd. | 14.48 Billion JPY | 104.996% |
| Linical Co., Ltd. | 1.24 Billion JPY | 158.037% |
| Trans Genic Inc. | 240.95 Million JPY | 400.414% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 46.613% |
| Soiken Holdings Inc. | -583.2 Million JPY | -24.116% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -20.024% |
| AnGes, Inc. | -8.86 Billion JPY | 91.83% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 43.691% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 90.217% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 665.039% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 16.124% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 33.7% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1449.19% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 6.671% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -547.449% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 40.263% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 47.578% |
| PeptiDream Inc. | 7.37 Billion JPY | 109.814% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 62.489% |
| Ribomic Inc. | -1.01 Billion JPY | 28.51% |
| SanBio Company Limited | -4.52 Billion JPY | 84.003% |
| Healios K.K. | -3 Billion JPY | 75.928% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 37.909% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 48.039% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 48.37% |
| StemRIM | -2.03 Billion JPY | 64.377% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 155.407% |
| FunPep Company Limited | -952 Million JPY | 23.965% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 18.555% |
| TMS Co., Ltd. | -937 Million JPY | 22.748% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 6.647% |
| Cuorips Inc. | -518 Million JPY | -39.74% |
| K Pharma,Inc. | 366.05 Million JPY | 297.743% |
| Takara Bio Inc. | 8.02 Billion JPY | 109.021% |
| ReproCELL Incorporated | 8.24 Million JPY | 8879.309% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 923.141% |
| StemCell Institute Inc. | 534.35 Million JPY | 235.463% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 395.675% |
| CellSeed Inc. | -836.51 Million JPY | 13.468% |